Celyad SA (CYAD): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYAD Stock Price Chart Interactive Chart >
CYAD Price/Volume Stats
| Current price | $2.10 | 52-week high | $6.40 |
| Prev. close | $2.09 | 52-week low | $1.51 |
| Day low | $2.10 | Volume | 2,100 |
| Day high | $2.16 | Avg. volume | 12,983 |
| 50-day MA | $2.10 | Dividend yield | N/A |
| 200-day MA | $3.45 | Market Cap | 33.80M |
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Latest CYAD News From Around the Web
Below are the latest news stories about Celyad Oncology SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.
Celyad Oncology Announces February 2022 Conference ScheduleMONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in February 2022: Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022Dates: Monday, February 14 to Friday, February 18, 2022Presentation: F |
Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year. |
Celyad Oncology Provides Outlook for 2022MONT-SAINT-GUIBERT, Belgium, January 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced a 2021 year-end review and provided an outlook for 2022. |
5 Beaten-Down Biotech Bets to Bounce Back in 2022Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options. |
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)MONT-SAINT-GUIBERT, Belgium, December 31, 2021--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the below information following the issuance on 8 December 2021 of 6,500,000 new shares of Celyad Oncology SA (the "Company") to an affiliate of Fortress Investment Group (such affiliate "Fo |
CYAD Price Returns
| 1-mo | 0.72% |
| 3-mo | -34.78% |
| 6-mo | -42.78% |
| 1-year | -61.75% |
| 3-year | -89.61% |
| 5-year | -94.74% |
| YTD | -42.62% |
| 2021 | -53.08% |
| 2020 | -25.14% |
| 2019 | -42.62% |
| 2018 | -57.87% |
| 2017 | 142.68% |
Continue Researching CYAD
Want to see what other sources are saying about Celyad Sa's financials and stock price? Try the links below:Celyad Sa (CYAD) Stock Price | Nasdaq
Celyad Sa (CYAD) Stock Quote, History and News - Yahoo Finance
Celyad Sa (CYAD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...